Glycosylation is a critical quality attribute vital for the structure and function of proteins. It can impact the immunogenicity and therapeutic efficacy of biopharmaceuticals, making it essential for regulatory approval of biosimilars.
The Cellvento® ModiFeed Platform provides a groundbreaking solution for modulating glycosylation profiles in biopharmaceutical development. This session will highlight how our concentrated complete feeds assist developers of biosimilars and innovator molecules. Discover the innovative ModiFeeds and their ability to enable precise titration of glycosylation, enhancing product quality and consistency, while ensuring no negative impact on growth or titer.
In this webinar, you will learn about:
- The concept of the Cellvento® ModiFeed Platform
- Application data of Cellvento® ModiFeed Platform
- Effective Strategies for Tackling Problems
- Use Cases for Innovators and Biosimilars
Speaker
Martina Grabner, Ph.D.
MilliporeSigma
Postdoctoral Research Scientist
Martina Grabner, Ph.D. is a postdoctoral research scientist in advanced cell culture technologies at MilliporeSigma. She earned her Ph.D. from the Technical University of Darmstadt and has been with the company since 2016. With nine years of experience in biotechnology, Grabner specializes in upstream processes, particularly focusing on the glycosylation of antibodies and fusion proteins. Her expertise has been instrumental in the development and successful launch of the innovative Cellvento® ModiFeeds, significantly advancing our capabilities in cell culture technologies.
Pharma and biopharma manufacturing
- Viral Vector Upstream Processing
Duration:1h
Language:English
Session 1:Thu, March 6, 2025 4:00 PM CEST
To continue reading please sign in or create an account.
Don't Have An Account?